Cancer Therapies From Dendreon and AEterna Zentaris Poised to Boost Profits

Five Star Equities Provides Stock Research on Dendreon & AEterna Zentaris

Marketwired

NEW YORK, NY--(Marketwire -02/27/12)- Advances in cancer screening and treatment has caused the death rate from cancer to drop in recent years. Cancer death rates dropped by 1.8 percent per year in men and 1.6 percent per year in women between 2004 and 2008, according to the American Cancer Society's annual report on cancer statistics. Five Star Equities examines the outlook for companies in the Biotechnology industry and provides equity research on Dendreon Corporation (NASDAQ: DNDN - News) and AEterna Zentaris, Inc. (NASDAQ: AEZS - News) (TSX: AEZ.TO - News). Access to the full company reports can be found at:

www.fivestarequities.com/DNDN

www.fivestarequities.com/AEZS

Death rates fell in all four of the most common cancers, lung, colon, breast and prostate, with lung cancer accounting for nearly 40 percent of the total drop in men and breast cancer account for 34 percent of the total decline in women, the American Cancer Society report finds.

The U.S. FDA has been approving cancer drugs at a faster rate than its European counterpart (the EMA), Friends of Cancer Research reports. Between 2003 and 2010, the FDA not only approved more new cancer drugs than did the EMA, it approved these drugs more quickly: of 23 drugs approved by both agencies, the median time from marketing submission to FDA approval was 182 days vs. EMA approval of 350 days according to the report.

Five Star Equities releases regular market updates on the biotechnology industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.fivestarequities.com and get exclusive access to our numerous stock reports and industry newsletters.

Aeterna Zentaris Inc. operates as a late-stage drug development company specialized in oncology and endocrine therapy. The company's lead oncology compounds include perifosine, which is in Phase 3 registration trial for refractory advanced colorectal cancer and multiple myeloma; and AEZS-108, a doxorubicin-targeted conjugate in Phase II for the treatment of ovarian, endometrial, castration refractory prostate, and refractory bladder cancer.

Dendreon Corporation, a biotechnology company, engages in the discovery, development, and commercialization of therapeutics to enhance cancer treatment options for patients.

Five Star Equities provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at:

www.fivestarequities.com/disclaimer

Contact:

Five Star Equities
Email Contact

View Comments (0)